Kyntra Bio (LTS:0IL8) Net Loan

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0IL8 Kyntra Bio Inc LTS:0IL8
53 GF Score
Price $6.83
GF Value $5.52
Valuation Modestly Overvalued
! 8 Warning Signs
View Full Analysis

What is Kyntra Bio Net Loan?

Net Loan only applies to banks and insurance companies.

LTS:0IL8
53GF Score
Kyntra Bio Inc LTS:0IL8
Net Loan is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Kyntra Bio (LTS:0IL8) Overvalued in 2026?

Based on GuruFocus' analysis, Kyntra Bio stock appears to be overvalued. The current stock price of $6.83 is trading 23.6% above its estimated GF Value™ of $5.52. GuruFocus considers Kyntra Bio to be Modestly Overvalued.

Key valuation signals for LTS:0IL8:

  • Net Loan:
  • GF Value™: $5.52 vs. price of $6.83 (23.6% above fair value)
  • GF Score™: 53/100 with 8 warning signs

No single metric tells the full story. See the LTS:0IL8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Kyntra Bio Business Description

Address 350 Bay Street, Suite 100, No. 6009, San Francisco, CA, USA, 94133
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
53GF Score

Get the complete analysis for LTS:0IL8

Net Loan is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.83
Price
$5.52
GF Value